HomeCompareIFLN vs PFE

IFLN vs PFE: Dividend Comparison 2026

IFLN yields 5.68% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $20.5K in total portfolio value· pulled ahead in Year 9
10 years
IFLN
IFLN
● Live price
5.68%
Share price
$17.95
Annual div
$1.02
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.1K
Annual income
$815.58
Full IFLN calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — IFLN vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIFLNPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IFLN + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IFLN pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IFLN
Annual income on $10K today (after 15% tax)
$482.56/yr
After 10yr DRIP, annual income (after tax)
$693.24/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,626.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IFLN + PFE for your $10,000?

IFLN: 50%PFE: 50%
100% PFE50/50100% IFLN
Portfolio after 10yr
$39.3K
Annual income
$13,537.15/yr
Blended yield
34.43%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

IFLN
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IFLN buys
0
PFE buys
0
No recent congressional trades found for IFLN or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIFLNPFE
Forward yield5.68%6.13%
Annual dividend / share$1.02$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$29.1K$49.6K
Annual income after 10y$815.58$26,258.71
Total dividends collected$7.0K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IFLN vs PFE ($10,000, DRIP)

YearIFLN PortfolioIFLN Income/yrPFE PortfolioPFE Income/yrGap
1$11,268$567.72$9,153$693.39+$2.1KIFLN
2$12,654$597.84$8,593$849.25+$4.1KIFLN
3$14,168$627.48$8,336$1,066.78+$5.8KIFLN
4$15,816$656.56$8,437$1,384.80+$7.4KIFLN
5$17,608$685.00$9,013$1,875.40+$8.6KIFLN
6$19,553$712.73$10,306$2,680.72+$9.2KIFLN
7$21,662$739.69$12,820$4,101.38+$8.8KIFLN
8$23,944$765.84$17,673$6,826.70+$6.3KIFLN
9← crossover$26,411$791.15$27,543$12,591.86$1.1KPFE
10$29,075$815.58$49,560$26,258.71$20.5KPFE

IFLN vs PFE: Complete Analysis 2026

IFLNStock

PHB invests in high-yield corporate bonds rated at Ba1/BB+ or lower but not below B3/B- by Moody's or S&P. The starting universe begins with all US-based publicly traded corporations that are scored by RAFI using four fundamental factors: book value of assets, gross sales, gross dividends, and cash flow. Only companies with positive scores are selected. There are two distinct maturity cells (15 years and 510 years) that the index employs, which allow up to two bonds per issuer. The issues are weighted proportionally to a companys RAFI score. The RAFI-patented fundamental weighting scheme normally results in overweighting of higher-quality bonds. The index is reconstituted monthly and rebalanced annually for new RAFI scores.

Full IFLN Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this IFLN vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IFLN vs SCHDIFLN vs JEPIIFLN vs OIFLN vs KOIFLN vs MAINIFLN vs JNJIFLN vs MRKIFLN vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.